深度聚焦！甘肃能源获国资委重组方案批复 股价领涨电力板块

甘肃能源获国资委重组方案批复 股价领涨电力板块

北京 - 6月13日，甘肃省国资委正式批复了甘肃能源（股票代码：000791）的重大资产重组方案。该方案的获批，为甘肃能源的未来发展注入了强劲动力，也提振了电力板块的整体行情。

重组方案亮点突出，利好公司长远发展

此次重组方案的核心内容是，甘肃省电力投资集团有限责任公司（以下简称“甘肃电力集团”）将以现金方式收购甘肃能源所持有的陇源电力（003916）全部股权。交易完成后，甘肃电力集团将成为陇源电力的控股股东，甘肃能源将持有甘肃电力集团100%的股权。

该重组方案具有以下亮点：

• **有利于优化甘肃省电力资源配置，提升行业竞争力。**甘肃电力集团是甘肃省最大的电力企业，陇源电力是甘肃省重要的电力上市公司。此次重组将整合双方资源，形成强强联合，有利于提升甘肃省电力行业的整体竞争力。
• **有利于推动甘肃能源转型升级，实现高质量发展。**甘肃电力集团在清洁能源领域具有较强的优势，此次重组将有利于甘肃能源加快清洁能源业务发展，实现转型升级。
• **有利于增强甘肃能源的资本实力，提升公司盈利能力。**甘肃电力集团的资产规模和盈利能力明显强于甘肃能源，此次重组将有利于增强甘肃能源的资本实力，提升公司盈利能力。

重组获批利好电力板块，甘肃能源股价涨停

甘肃能源重大资产重组方案获批的消息，利好整个电力板块。6月13日，A股电力板块整体涨幅达2.3%，其中甘肃能源股价涨停，收报7.15元/股，涨幅达4.67%。

市场人士预计，甘肃能源在重组完成后将迎来新的发展机遇，公司股价有望继续上行。

以下是一些分析人士对甘肃能源未来发展的看法：

• 某券商分析师表示，甘肃能源此次重组是强强联合，有利于公司做大做强，提升核心竞争力。看好公司未来发展前景，建议投资者关注。
• 另一位分析师则认为，甘肃能源重组后将受益于甘肃电力集团的资源优势和管理经验，有望在清洁能源领域取得更大突破。建议投资者重点关注公司清洁能源业务的发展。

总而言之，甘肃能源重大资产重组方案的获批，是公司发展史上的重要里程碑，有利于公司实现高质量发展，也为投资者带来了新的投资机会。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.